Mission
The Alzheimer's Drug Discovery Foundation (ADDF) is focused on rapidly advancing the development of drugs to prevent, treat, and cure Alzheimer's disease. Founded in 1998, it employs a venture philanthropy model to fund promising research projects around the globe, aiming to bridge critical funding gaps in Alzheimer's drug discovery.
Basic Information
Tax-Exempt
Founded in
2004
EIN
20-1082179
Total Assets
$340.3 million
UN Sustainable Development Goals Supported
This organization contributes to the following United Nations Sustainable Development Goals. See the SDG page for more information.
Showing 2 of 2 goals
At a Glance
ADDF's Unique Funding Approach
ADDF utilizes a venture philanthropy model to fund innovative drug discovery research.
Innovations in Alzheimer's Diagnostics
The foundation has funded the development of key diagnostic tools for early Alzheimer’s detection.
Global Reach of ADDF Funding
ADDF supports projects in more than 20 countries, fostering global collaboration in Alzheimer’s research.
Impact Stats
$290 million
Total Funding
Funding for Alzheimer's Research
ADDF has awarded over $290 million to support drug discovery programs, biomarkers, and clinical trials for Alzheimer's.
30+
Number of Clinical Trials
Clinical Trials Portfolio
ADDF runs one of the largest and most diverse clinical development portfolios for Alzheimer's, with over 30 active trials.
$3 billion
Follow-on Funding Generated
Venture Philanthropy Model
By leveraging a venture philanthropy model, ADDF has enabled significant follow-on funding for researchers, totaling over $3 billion.
Past Events
Third Annual House of Purple
November 14, 2024
Tribeca Rooftop hosted the Third Annual House of Purple, fundraising for ADDF's mission.
Fourteenth Annual Fall Symposium & Luncheon
November 7, 2024
The Fourteenth Annual Fall Symposium & Luncheon brought together researchers and advocates.
2024 TCS NEW YORK CITY MARATHON
November 3, 2024
Participants in the 2024 TCS New York City Marathon raised funds for ADDF.
Upcoming Events
Palm Beach Scientific Summit
March 5, 2025
A gathering of leaders in Alzheimer’s research to discuss advancements and foster collaboration.
Learn MoreOur Programs
Clinical Development Programs
The ADDF supports and manages various clinical development programs focused on Alzheimer's treatments.
Learn MoreDiagnostics Accelerator
A program to fund innovative diagnostic technologies for Alzheimer's disease.
Learn MoreImpact Reports
MIP Score (Beta)
The MIP Score is in beta! We'd love any feedback you may have.
The MIP Score and it's methodology is purely used as a way to visualize how a nonprofits public financial data compares against others. It doesn't reflect the unique circumstances and impact that a nonprofit has.The MIP Score should never be used to say one charity is better than another.
Overall Score
69
64
/100
Program Expense Ratio
97.79%
20
/20
Program Revenue Growth
-29.71%
2
/20
Leverage Ratio
0.1668
16
/20
Working Capital Ratio
7.695
20
/20
Fundraising Efficiency
6.845
6
/20
Latest Filing Data: Form 990
Fiscal Year:2022
Source:Source: Self-reported by organization
Financial Details
Revenue
| Category | Amount | Percentage |
|---|---|---|
| Contributions, Gifts, and Grants | 249.8M | 98.35% |
| Program Services | 6.426M | 2.53% |
| Investment Income | 857.7K | 0.34% |
| Sales of Non-Inventory Assets | -2.912M | -1.15% |
| Other Notable Sources | 0 | 0.00% |
| Total Revenue | 254M | 100.00% |
Related Nonprofits
Morning Pointe Foundation
Social Science
Aging Research InstituteAlzheimers Drug Discovery Foundation
Social Science
Aging Research Institute
Margaret D Smock Charitable Trust
Social Science
Aging Research InstituteArea Agencies on Aging Association of Michigan
Social Science
Aging Research InstituteAmerican Federation for Aging
Social Science
Aging Research Institute